Clene raises $7M via stock offering to fund ALS drug development and trials

Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced a $7 million underwritten offering of 1 million common shares at $7 each to a single investor. The funds will support general corporate expenses and advance the development of their lead drug candidate CNM-Au8®, including NDA preparation, ongoing and future clinical trials, manufacturing expansion, and early-stage research. The offering is expected to close around May 6, 2026. This capital raise is crucial for Clene's efforts to bring new treatments for diseases like ALS and multiple sclerosis to market.